Tumor-associated macrophages in diffuse large B-cell lymphoma.
作者信息
Kridel Robert, Steidl Christian, Gascoyne Randy D
机构信息
Department of Lymphoid Cancer Research, BC Cancer Agency and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Department of Lymphoid Cancer Research, BC Cancer Agency and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
出版信息
Haematologica. 2015 Feb;100(2):143-5. doi: 10.3324/haematol.2015.124008.
Abstract
摘要
相似文献
1
Tumor-associated macrophages in diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤中的肿瘤相关巨噬细胞
Haematologica. 2015 Feb;100(2):143-5. doi: 10.3324/haematol.2015.124008.
2
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.巨噬细胞对弥漫性大B细胞淋巴瘤患者的预后影响：一项来自北欧II期试验的相关性研究。
Haematologica. 2015 Feb;100(2):238-45. doi: 10.3324/haematol.2014.113472. Epub 2014 Nov 7.
3
Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.原发性睾丸弥漫性大B细胞淋巴瘤伴中枢神经系统进展患者的嵌合抗原受体T细胞疗法成功案例。
Leuk Lymphoma. 2019 Nov;60(11):2814-2816. doi: 10.1080/10428194.2019.1605507. Epub 2019 May 14.
4
Heart as the site of first relapse in diffuse large B-cell lymphoma.心脏作为弥漫性大B细胞淋巴瘤首次复发的部位。
Indian J Cancer. 2010 Apr-Jun;47(2):220-2. doi: 10.4103/0019-509X.62999.
5
Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.利妥昔单抗联合α干扰素治疗复发难治性弥漫性大B细胞非霍奇金淋巴瘤
Acta Haematol. 2001;106(3):141-2. doi: 10.1159/000046607.
6
Early CNS relapse in a good-risk primary mediastinal large B-cell lymphoma after combined chemo- and radio-therapy.在接受化疗和放疗联合治疗后，预后良好的原发性纵隔大B细胞淋巴瘤出现早期中枢神经系统复发。
J Neurooncol. 2010 Sep;99(2):295-6. doi: 10.1007/s11060-010-0132-x. Epub 2010 Feb 13.
7
Clinical approach to diffuse large B cell lymphoma.弥漫性大B细胞淋巴瘤的临床治疗方法
Blood Rev. 2016 Nov;30(6):477-491. doi: 10.1016/j.blre.2016.06.003. Epub 2016 Jun 30.
8
[Intra-tumoral hemorrhage of a relapsed CNS diffuse large B-cell lymphoma: a case report].[复发性中枢神经系统弥漫性大B细胞淋巴瘤瘤内出血：一例报告]
No Shinkei Geka. 2014 Jul;42(7):651-8.
9
Polymyositis following autologous haematopoietic stem cell transplantation.
Scand J Rheumatol. 2016 Oct;45(5):429-31. doi: 10.3109/03009742.2015.1125525. Epub 2016 Apr 6.
10
Primary diffuse large B-cell lymphoma of the palpebral conjunctiva.
Can J Ophthalmol. 2007 Aug;42(4):630-1.
引用本文的文献
1
VSIG4 as a tumor-associated macrophage marker predicting adverse prognosis in diffuse large B-cell lymphoma.VSIG4作为一种肿瘤相关巨噬细胞标志物可预测弥漫性大B细胞淋巴瘤的不良预后。
Front Immunol. 2025 Jun 5;16:1567035. doi: 10.3389/fimmu.2025.1567035. eCollection 2025.
2
Critical Role of Extracellular Vesicles in Diffuse Large B-Cell Lymphoma; Pathogenesis, Potential Biomarkers, and Targeted Therapy-A Narrative Review.细胞外囊泡在弥漫性大B细胞淋巴瘤中的关键作用；发病机制、潜在生物标志物及靶向治疗——一篇叙述性综述
Biomedicines. 2024 Dec 12;12(12):2822. doi: 10.3390/biomedicines12122822.
3
Prognostic Significance of T-Cells and Macrophages in the Tumour Microenvironment of Nodal DLBCL.T细胞和巨噬细胞在淋巴结弥漫性大B细胞淋巴瘤肿瘤微环境中的预后意义
Indian J Hematol Blood Transfus. 2024 Oct;40(4):604-612. doi: 10.1007/s12288-024-01770-6. Epub 2024 Apr 12.
4
Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.阻断CD47/SIRPα检查点轴可增强tafasitamab的巨噬细胞介导的抗肿瘤功效。
Haematologica. 2024 Dec 1;109(12):3928-3940. doi: 10.3324/haematol.2023.284795.
5
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.赋能巨噬细胞：肿瘤微环境中的癌症斗士——套细胞淋巴瘤。
Front Immunol. 2024 Mar 19;15:1373269. doi: 10.3389/fimmu.2024.1373269. eCollection 2024.
6
Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma.空间分辨转录组学揭示弥漫性大 B 细胞淋巴瘤中巨噬细胞的异质性和预后意义。
Nat Commun. 2024 Mar 8;15(1):2113. doi: 10.1038/s41467-024-46220-z.
7
The Oncogenic Lipid Sphingosine-1-Phosphate Impedes the Phagocytosis of Tumor Cells by M1 Macrophages in Diffuse Large B Cell Lymphoma.致癌脂质鞘氨醇-1-磷酸阻碍弥漫性大B细胞淋巴瘤中M1巨噬细胞对肿瘤细胞的吞噬作用。
Cancers (Basel). 2024 Jan 29;16(3):574. doi: 10.3390/cancers16030574.
8
Tumor-derived Exosomal ENO2 Modulates Polarization of Tumor-associated Macrophages through Reprogramming Glycolysis to Promote Progression of Diffuse Large B-cell Lymphoma.肿瘤来源的外泌体 ENO2 通过重编程糖酵解来调节肿瘤相关巨噬细胞的极化，从而促进弥漫性大 B 细胞淋巴瘤的进展。
Int J Biol Sci. 2024 Jan 1;20(3):848-863. doi: 10.7150/ijbs.91154. eCollection 2024.
9
The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma.可溶性MICA/可溶性MICB对新诊断弥漫性大B细胞淋巴瘤免疫化疗疗效的影响。
Front Oncol. 2023 Nov 16;13:1194315. doi: 10.3389/fonc.2023.1194315. eCollection 2023.
10
Immunohistochemical Expression of Programmed Death Ligand 1 in Oral Extranodal Diffuse Large B Cell Lymphoma.程序性死亡配体1在口腔结外弥漫性大B细胞淋巴瘤中的免疫组化表达
Eur J Dent. 2023 May;17(2):424-430. doi: 10.1055/s-0042-1747951. Epub 2022 Aug 9.
本文引用的文献
1
Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP.使用组织芯片和免疫组化技术重新审视弥漫性大B细胞淋巴瘤的免疫微环境：强大的半自动分析揭示CD3和FoxP3作为R-CHOP治疗反应的潜在预测指标。
Haematologica. 2015 Mar;100(3):363-9. doi: 10.3324/haematol.2014.110189. Epub 2014 Nov 25.
2
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.巨噬细胞对弥漫性大B细胞淋巴瘤患者的预后影响：一项来自北欧II期试验的相关性研究。
Haematologica. 2015 Feb;100(2):238-45. doi: 10.3324/haematol.2014.113472. Epub 2014 Nov 7.
3
Microvascular density, CD68 and tryptase expression in human diffuse large B-cell lymphoma.人类弥漫性大 B 细胞淋巴瘤中的微血管密度、CD68 和类胰蛋白酶表达。
Leuk Res. 2014 Nov;38(11):1374-7. doi: 10.1016/j.leukres.2014.09.007. Epub 2014 Sep 22.
4
The tumour microenvironment in B cell lymphomas.B 细胞淋巴瘤的肿瘤微环境。
Nat Rev Cancer. 2014 Aug;14(8):517-34. doi: 10.1038/nrc3774. Epub 2014 Jul 10.
5
High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤患者诊断时CD68+/CD163+肿瘤相关巨噬细胞（M2-TAM）的高密度与不良预后因素及不良临床结局显著相关。
Hematol Oncol. 2015 Jun;33(2):110-2. doi: 10.1002/hon.2142. Epub 2014 Apr 8.
6
Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤患者流式细胞术检测的人类白细胞抗原-DR表达及肿瘤相关巨噬细胞：回顾性队列研究
Leuk Lymphoma. 2014 Dec;55(12):2721-7. doi: 10.3109/10428194.2014.893311. Epub 2014 Mar 19.
7
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.M2巨噬细胞数量增加预示着接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤患者预后不良。
Leuk Lymphoma. 2014 Nov;55(11):2466-76. doi: 10.3109/10428194.2013.879713. Epub 2014 Mar 3.
8
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.Fcγ 受体多态性在癌症中对单克隆抗体反应的作用的批判性评价。
J Hematol Oncol. 2013 Jan 4;6:1. doi: 10.1186/1756-8722-6-1.
9
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.剂量密集化疗联合免疫治疗后行全身中枢神经系统预防治疗用于年轻高危弥漫大 B 细胞淋巴瘤/滤泡性淋巴瘤 3 级患者：一项北欧淋巴瘤组 II 期研究结果。
Ann Oncol. 2013 May;24(5):1385-92. doi: 10.1093/annonc/mds621. Epub 2012 Dec 17.
10
Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes.间充质基质细胞通过 CCL2 依赖性招募和单核细胞极化来协调滤泡性淋巴瘤细胞生态位。
Blood. 2012 Mar 15;119(11):2556-67. doi: 10.1182/blood-2011-08-370908. Epub 2012 Jan 30.
Zotero 插件